FDA Determines Regulatory Review Period for Xience Xpedition Everolimus Eluting Coronary Stent System

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the review period for the Xience Xpedition Everolimus Eluting Coronary Stent System, a medical device, in accordance with federal regulations, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).